Open AccessMarkedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021
Author(s) -
Regina Selb,
Susanne Buder,
Sandra Dudareva,
Thalea Tamminga,
Viviane Bremer,
Sebastian Banhart,
Dagmar Heuer,
Klaus Jansen
Publication year - 2021
Publication title -
euro surveillance/eurosurveillance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.766
H-Index - 104
eISSN - 1560-7917
pISSN - 1025-496X
DOI - 10.2807/1560-7917.es.2021.26.31.2100616
Subject(s) - azithromycin , neisseria gonorrhoeae , medicine , epidemiology , antimicrobial , minimum inhibitory concentration , neisseria , gonorrhea , microbiology and biotechnology , antibiotics , virology , biology , human immunodeficiency virus (hiv) , bacteria , genetics
We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.